BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE

VolverGo back

Resultados 112 results. LastUpdate Updated on 14/08/2022 [12:56:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



Page1/5 nextPage   results/page


INTEGRATED DEVICE FOR MEDICAL SAMPLING AND TESTING

Publication No.: US2022249070A1 11/08/2022

Applicant:

JIANGSU GEMKEEPER BIOTECH COMPANY LTD [CN]

EP_3926322_PA

Absstract of: US2022249070A1

An integrated device for medical sampling and testing, comprising a sampling rod (15) and a casing. A test paper accommodating cavity (2) and a diluent cavity (5) are included in the casing. A liquid outlet (4) is provided at a bottom part of the diluent cavity (5), and a hole-plugging object (14) is provided on the liquid outlet (4). The preset device has a simple structure, and may simultaneously achieve the sampling, dilution and testing of feces. Moreover, the device may integrate the collection, dilution, mixing, sample addition and testing of a feces sample, so that an ordinary person may screen people at home who are at high-risk for bowel and stomach cancer, which is of great social significance. The device has a clever structure, is easy to use, and also ensures the pre-filled diluent is sealed in.

traducir

METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNF ALPHA THERAPY IN INFLAMMATORY BOWEL DISEASE

Publication No.: US2022251656A1 11/08/2022

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

US_2019010549_A1

Absstract of: US2022251656A1

The present invention relates to methods of prognosing responsiveness to anti-TNFα therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNFα therapy in an individual diagnosed with IBD.

traducir

METHOD FOR DIAGNOSIS OF COLITIS THROUGH QPCR ANALYSIS

Publication No.: US2022251636A1 11/08/2022

Applicant:

MD HEALTHCARE INC [KR]

KR_20200134909_A

Absstract of: US2022251636A1

Provided is a method of diagnosing colitis through qPCR analysis and to a method of diagnosing colitis by measuring amounts of microorganisms in stool samples to be analyzed. The diagnosis method according to the presently claimed subject matter can predict and/or diagnose colitis at high accuracy and sensitivity by using stool, which can be easily acquired without pain from a subject to be diagnosed, and as such, can find a wide range of applications in the colitis diagnosis field and, as a result, is expected to enable early diagnosis of colitis, thereby remarkably increasing the effects of colitis treatment.

traducir

USES OF PATIENT-DERIVED INTESTINAL ORGANOIDS FOR CELIAC DISEASE DIAGNOSIS, SCREENING AND TREATMENT

Publication No.: JP2022535274A 05/08/2022

Applicant:

ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー

US_2022221445_A1

Absstract of: WO2020247528A1

Air-liquid interface organoid cultures are initiated from human small intestine biopsy tissue comprising both the syngeneic intestinal epithelium and native intestinal immune cells, without reconstitution, which may be obtained from an individual pre-disposed or suffering from celiac disease. The organoid cultures exhibit T cell activation in response to in vitro gluten challenge and provide tools for a novel diagnostic method for celiac disease. Diagnosis may comprise the addition of immunogenic gluten-derived peptides into the organoid cultures, and assessing hallmarks of active celiac disease, including without limitation: 1) gliadin-presentation, resulting T-cell responses, such as 2) expansion and 3) activation, 4) epithelial-cell death and consequent 5) increased proliferative epithelial cell responses to gliadin. Celiac patients, either in GRD or GFD, test positive for these tests. In other embodiments the organoids are used to test responses to candidate therapeutic agents, assessing reduction of gliadin-dependent (1) T cell activation or expansion, or (2) organoid epithelial cell death.

traducir

MATERIALS AND METHODS FOR DETERMINING CANCER RISK

Publication No.: US2022244262A1 04/08/2022

Applicant:

MAYO FOUND MEDICAL EDUCATION & RES [US]

US_2018364239_A1

Absstract of: US2022244262A1

This document relates to materials and methods involved in assessing inflammatory bowel disease patients at risk for developing cancer. For example, materials and methods for monitoring colorectal cancer risk in ulcerative colitis patients are provided.

traducir

Epitope-Based Approach for Allergy Treatments and Inhibitors for Crohn's Disease

Publication No.: US2022233686A1 28/07/2022

Applicant:

PSOMAGEN INC [US]

JP_2022524757_A

Absstract of: US2022233686A1

The present disclosure relates to pharmaceutical compounds and compositions and methods for treating an allergy and Crohn's disease. Methods for treating an allergy can include (a) predicting potential epitopes based proteomes of microbiome and that of an allergen, (b) filtering the potential epitopes obtained in step a) to result in a list of epitopes; and (c) reengineering the list of epitopes obtained in step b) to result in the new epitope. Methods for treating Crohn's disease can include (a), identifying one or more binding regions of an HLA class II protein and/or hemagglutinin to I2 superantigen; (b) determining a first peptide sequence corresponding to the one or more binding regions, and (c) producing a peptide inhibitor having a second peptide sequence that is a mutation of the first peptide sequence, wherein the second peptide sequence has a stronger binding affinity to the I2 superantigen than the first peptide sequence.

traducir

INTESTINAL ORGANOID IMMUNE-CONTROL INTEGRATED PLATFORM FOR THERAGNOSIS OF MICROBIOME AND IMMUNE CELL

Publication No.: WO2022158882A1 28/07/2022

Applicant:

CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]

Absstract of: WO2022158882A1

It was identified that intestinal organoids derived human blood and endocytes of the present invention expressed the intestinal differentiation markers CGA, CDX2, LYZ, ECAD, KLF5, MUC2, Ki67, VIL, LGR5, SOX9, VIM, and SMA, thereby effectively reflecting intestinal conditions and can assay intestinal protection and intestinal secretions according to treatment with microbiomes. In addition, the (Bifidobacterium microbiome RAPO of the present invention was identified to upregulate the expression of IL-10 and REG3A and induce the expression of lysozyme, E-cadherin, and CGA and the proliferation of intestinal crypts in the intestinal organoids. Furthermore, intestinal organoids of the present invention were examined for responses to treatment with homologous PBMC to identify the reactivity of transplant rejection. In addition, an inflammatory bowel disease simulated avatar model of the present invention was identified to allow for effectively engrafting human blood immune cells thereto and induce the development of inflammatory bowel disease and the injury of intestinal tissues, thereby effectively reflecting diseased conditions of patients. Also, it was identified that injection of PBMC from patients with inflammatory bowel disease advanced the inflammatory bowel diseases, compared to injection of PBMC from normal persons and treatment with candidate materials could palliate the inflammatory bowel diseases, whereby therapeutic agents customized for patients can be screened.

traducir

Compositions and methods for treating inflammatory bowel disease

Publication No.: AU2020407659A1 28/07/2022

Applicant:

ICAHN SCHOOL MED MOUNT SINAI

WO_2021127598_A1

Absstract of: AU2020407659A1

The present invention provides methods of diagnosing, treating, and monitoring the progression of inflammatory bowel disease in a subject, including, for example, by monitoring ROR

traducir

METHODS OF TREATING DISEASES

Publication No.: EP4032906A1 27/07/2022

Applicant:

BOEHRINGER INGELHEIM INT [DE]

EP_3848390_PA

Absstract of: EP4032906A1

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.

traducir

BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITIS

Publication No.: EP4032586A1 27/07/2022

Applicant:

REBIOTIX INC [US]

ES_2916399_T3

Absstract of: EP4032586A1

This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.

traducir

Type XXIII Collagen Assay

Publication No.: US2022227848A1 21/07/2022

Applicant:

NORDIC BIOSCIENCE AS [DK]

JP_2022519728_A

Absstract of: US2022227848A1

The present invention provides monoclonal antibodies that target collagen type XXIII, and to immunoassays and kits employing the antibodies for detecting and quantifying the epitope. The invention also provides a method for identifying and monitoring subjects with inflammatory bowel disease.

traducir

Diagnosis and treatment of autoimmune diseases

Publication No.: AU2022204649A1 21/07/2022

Applicant:

TAKEDA PHARMACEUTICALS CO [JP]

ES_2873204_T3

Absstract of: AU2022204649A1

DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

traducir

USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS

Publication No.: JP2022106732A 20/07/2022

Applicant:

ジェネンテック,インコーポレイテッド

EP_3933401_A2

Absstract of: WO2014160753A1

Methods of assessing or monitoring the effect, efficacy, responsiveness to treatment, and/or determining a dose or dosing regimen of therapeutic agents, such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of using integrin beta7 subunit-containing receptor occupancy by the integrin beta7 antagonist on colonic lymphocytes as an indicator ("biomarker") of the effect, efficacy, or responsiveness to treatment, and/or as a means to determine dosing or dosing regimens of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of assessing the effect, efficacy, or responsiveness to beta7 integrin antagonist treatment by measuring gene expression levels of one or more integrin receptor ligands, lymphocyte genes, cytokine genes, or the number of alphaE-positive cells in intestinal crypt epithelium are provided.

traducir

MUCINS AND ISOFORMS THEREOF IN DISEASES CHARACTERIZED BY BARRIER DYSFUNCTION

Publication No.: EP4029516A1 20/07/2022

Applicant:

UNIV ANTWERPEN [BE]

Absstract of: EP4029516A1

The present invention relates to the field of mucins and isoforms thereof, more in particular for use in the diagnosis, monitoring, prevention and/or treatment of a disease characterized by barrier dysfunction, such as but not limited to a gastrointestinal disorder (e.g. Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), cancer, gastro-intestinal infections, obesitas, non-alcoholic fatty liver disease (NAFLD)), neurodegenerative disorders, respiratory infections,... more in particular coronaviral infections In a specific embodiment, said mucins and/or isoforms thereof are selected from the list comprising: MUC16, MUC21, MUC2, MUC4, MUC5AC, MUC5B, MUC13, and MUC1 and isoforms thereof

traducir

USES OF PATIENT-DERIVED INTESTINAL ORGANOIDS FOR CELIAC DISEASE DIAGNOSIS SCREENING AND TREATMENT

Publication No.: US2022221445A1 14/07/2022

Applicant:

THE BOARD OF TRUSTEESOFTHELELANDSTANFORDJUNIORUNIVERSITY [US]

JP_2022535274_A

Absstract of: US2022221445A1

Air-liquid interface organoid cultures are initiated from human small intestine biopsy tissue comprising both the synintestinal epithelium and native intestinal immune cells, without reconstitution, which may be obtained from an individual pre-disposed or suffering from celiac disease. The organoid cultures exhibit T cell activation in response to in vitro gluten challenge and provide tools for a novel diagnostic method for celiac disease. Diagnosis may comprise the addition of immunogenic gluten-derived peptides into the organoid cultures, and assessing hallmarks of active celiac disease, including without limitation: 1) gliadin-presentation, resulting T-cell responses, such as 2) expansion and 3) activation, 4) epithelial-cell death and consequent 5) increased proliferative epithelial cell responses to gliadin. Celiac patients, either in GRD or GFD, test positive for these tests. In other embodiments the organoids are used to test responses to candidate therapeutic agents, assessing reduction of gliadin-dependent (1) T cell activation or expansion, or (2) organoid epithelial cell death.

traducir

Pharmaceutical composition for treatment or prevention of multiple inflammatory disorders

Publication No.: AU2020414720A1 14/07/2022

Applicant:

AARDVARK THERAPEUTICS INC

WO_2021133908_A1

Absstract of: AU2020414720A1

There is disclosed a method for treatment, prevention, and/or slowing of progression for various chronic inflammatory disorder groups including (1) type 2 diabetes group (metabolic syndrome (MET), obesity, hyperglycemia); (2) ARDS (acute respiratory distress syndrome); (3) chronic autoimmune inflammatory disorders (rheumatoid arthritis (RA), lupus, and psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolome-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) hyperphagia disorders such as Prader-Willi Syndrome and other monogenic and syndromic obesity disorders including leptin pathway deficiencies, each comprising administering orally a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on readouts from a series of studies tracking clusters of biomarkers levels to track mediators of inflammatory disorders and mediators of gutsignaling hormones in response to orally administered denatonium salts.

traducir

Use of Reagent for Detecting Expression Level of Transferrin in Preparation of Diagnostic Reagent or Kit for Disease Caused by Imbalance of Intestinal Immune Tolerance

Publication No.: US2022221471A1 14/07/2022

Applicant:

KUNMING INST ZOOLOGY CAS [CN]

JP_2022525824_A

Absstract of: US2022221471A1

The present disclosure provides use of a reagent for detecting an expression level of transferrin in the preparation of a diagnostic reagent or kit for a disease caused by imbalance of intestinal immune tolerance, and belongs to the technical field of medical molecular biology. In the present disclosure, the severity of intestinal inflammatory diseases is diagnosed according to the transferrin level, achieving the objective of the early diagnosis of the disease caused by imbalance of intestinal immune tolerance. In the present disclosure, the transferrin is used as a marker for imbalance of intestinal immune tolerance, featuring high specificity and sensitivity, and simple detection procedure.

traducir

INDUCED HUMAN COLITIC ORGANOIDS

Publication No.: US2022220448A1 14/07/2022

Applicant:

CLEVELAND CLINIC FOUND [US]

WO_2020232086_A1

Absstract of: US2022220448A1

Provided herein are compositions, systems, kits, and methods that employ a colitic induced human colitic organoid (iHCO) that has both an epithelial compartment and mesenchymal compartment, and provides at least one feature (e.g., leaky epithelial barrier) of IBD patient tissue (e.g., ulcerative colitis or Crohn's disease tissue). In certain embodiments, such iHCO's are employed in vitro or in vivo to screen candidate IBD treating compounds (e.g., to determine effectiveness for a particular patient who was the source of the original colonic fibroblasts used to generate the iHCO).

traducir

EXCREMENT DETERMINATION METHOD, EXCREMENT DETERMINATION DEVICE, AND EXCREMENT DETERMINATION PROGRAM

Publication No.: WO2022149342A1 14/07/2022

Applicant:

PANASONIC HOLDINGS CORP [JP]

Absstract of: WO2022149342A1

This excrement determination device obtains image data of excrement captured by a camera for imaging the interior of the bowl of a toilet, calculates a G/R value and a B/R value on the basis of the R (red) value, the G (green) value and the B (blue) value included in the image data, determines whether or not said image data includes an image of a bowel movement, urination and/or bleeding on the basis of the G/R value and the B/R value, and outputs the determination results.

traducir

ASSAY DETECTION METHODS FOR VCAM-1 AND CALPROTECTIN

Publication No.: JP2022532381A 14/07/2022

Applicant:

プロサイセデクスインコーポレイティド

US_2021405063_A1

Absstract of: WO2020232262A1

Assay methods for detecting the presence or amount of VCAM-1 or calprotectin in a sample using fluorescence resonance energy transfer (FRET).

traducir

DOSAGE REGIMEN FOR MADCAM ANTAGONISTS

Publication No.: CN114732899A 12/07/2022

Applicant:

辉瑞公司

CN_114377125_A

Absstract of: WO2016110806A2

The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody. Biomarkers for assessing a patient's response to anti-MAdCAM treatment are also provided.

traducir

Debaryomyces species as an indicator of non-healing ulcers in Crohn's disease

Publication No.: AU2020403007A1 07/07/2022

Applicant:

UNIV WASHINGTON

WO_2021119358_A1

Absstract of: AU2020403007A1

Methods for treating, selecting a treatment, and monitoring a treatment for an inflammatory bowel disease in a patient in need are disclosed. Treatments include administering an antifungal compound. The method for selecting and monitoring a treatment includes detecting a biomarker indicative of an amount of the fungus Debaryomyces hansenii within the sample. The treatment is administered if the biomarker is above a threshold level and the biomarker may be monitored before and during treatment. Biomarkers include abundance of fungal DNA in the patient's gut microbiota and anti-fungal antibodies in the blood of the patient.

traducir

METHOD OF DETERMINING THE PROBABILITY OF INFLAMMATORY BOWEL DISEASE IN A SUBJECT BEING ULCERATIVE COLITIS OR CROHN'S DISEASE

Publication No.: US2022214357A1 07/07/2022

Applicant:

UNIV LIMERICK [IE]

WO_2020221942_A1

Absstract of: US2022214357A1

The Applicant has discovered a cytokine profile that can accurately distinguish between ulcerative colitis (UC) and Crohn's disease (CD) in a subject having, or having symptoms of, inflammatory bowel disease (IBD). The profile of ulcerative colitis is increased IL-10 levels (compared with a reference IL-10 level, and decreased IL-23 levels (compared with a reference IL-23 level). The cytokine profile can be detected at a protein or genomic level, and is generally determined from a peripheral blood sample (i.e. a blood fraction such as serum, plasma, or blood cells such as peripheral blood mononuclear cells). Distinguishing between UC and CD in a subject with IBD allows a clinician prescribe a suitable therapeutic regime for the subject using a non-invasive blood test, and avoiding the need for scoping or tissue biopsy, which are undesirable for the subject. The cytokine profile can also be used to monitor a therapeutic regime for effectiveness.

traducir

METHOD FOR JUDGING ONSET POSSIBILITY OF LARGE BOWEL CANCER

Publication No.: EP4023162A2 06/07/2022

Applicant:

HANUMAT CO LTD [JP]
EA PHARMA CO LTD [JP]

US_2022022851_A1

Absstract of: EP4023162A2

The present invention provides a method for determining the likelihood of colorectal cancer development in a human ulcerative colitis patient, the method including: a measurement step of measuring methylation rates of one or more CpG sites present in specific differentially methylated regions in DNA recovered from a biological sample collected from the human ulcerative colitis patient; and a determination step of determining the likelihood of colorectal cancer development in the human ulcerative colitis patient based on average methylation rates of the differentially methylated regions which are calculated based on the methylation rates measured in the measurement step and a preset reference value or a preset multivariate discrimination expression, in which the reference value is a value for identifying a cancerous ulcerative colitis patient and a non-cancerous ulcerative colitis patient, which is set for the methylation rate of each differentially methylated region, and the multivariate discrimination expression includes, as variables, average methylation rates of one or more differentially methylated regions among the specific differentially methylated regions.

traducir

TL1A THERAPY COMPOSITIONS AND METHODS OF TREATMENT THEREWITH

Nº publicación: WO2022140283A1 30/06/2022

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

Absstract of: WO2022140283A1

Disclosed herein are methods, kits and compositions for treating an inflammatory disease or condition, or fibrosis in a subject that has been determined to have increased fold-change in Tumor necrosis factor (TNF)-like cytokine 1A (TL1A) expression based, at least partially, on a presence of a combination of genotypes detected in a sample obtained from the subject. In some embodiments, the combination of genotypes is significantly associated with the increased fold-change in TL1A, and in some cases, may also be predictive of severe forms of the inflammatory disease or condition. In some embodiments, the inflammatory disease or condition is an inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.

traducir

Page1/5 nextPage results/page

punteroimgGo back